AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31304593
Drug: 800 μg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 μg of rectal misoprostol after abdominal closure (postoperative group, n=100)
Trial: 28914260
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (Hd‐MTX) therapy (3 g/m2)
Trial: 28914260
Drug: Intermediate-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose methotrexate (Id‐MTX) therapy (0.5 g/m2)
Trial: 24642289
Drug: L-Dopa (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Dopa (150 mg)
Trial: 20621900
Drug: Enoxaparin, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin, 40 mg/d subcutaneously for 28 +/- 4 days after receiving open-label enoxaparin for an initial 10 +/- 4 days.
Trial: 16351767
Drug: Soyabean oil-based
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soyabean oil-based intravenous lipid emulsion (ILE)
Trial: 11942872
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (Group E)
Trial: 11942872
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (Group P)
Trial: 2698567
Drug: Gallopamil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil (3 X 50 mg daily for 4 weeks)
Trial: 1093651
Drug: Co-trimoxazole (trimethoprim,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (trimethoprim, 80 mg and sulfamethoxazole, 400 mg) - single dose
Trial: 1093651
Drug: Co-trimoxazole (trimethoprim,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (trimethoprim, 80 mg and sulfamethoxazole, 400 mg) - two doses
Trial: 1093651
Drug: TMP-SDZ (sulfadiazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP-SDZ (sulfadiazine, 400 mg and trimethoprim, 80 mg) - single dose
Trial: 1093651
Drug: TMP-SDZ (sulfadiazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP-SDZ (sulfadiazine, 400 mg and trimethoprim, 80 mg) - two doses
Trial: 25272194
Drug: Maximum ARB
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum ARB dose
Trial: 25272194
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg/hydrochlorothiazide 12.5 mg combination
Trial: 19471949
Drug: IV siplizumab
RxNorm normalized name: teplizumab
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV siplizumab (0.012 mg/kg and 0.04 mg/kg) given every 2 weeks for 8 doses
Trial: 19471949
Drug: SC siplizumab
RxNorm normalized name: teplizumab
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC siplizumab (5 mg for 12 weeks, 5 mg for 6 weeks, and 7 mg for 4 weeks)
Trial: 16505664
Drug: Sequential gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential gas delivery (SGD) mask at 8 L/min
Trial: 12867391
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% and dorzolamide 2% fixed combination (TDFC) given twice daily
Trial: 12867391
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% and dorzolamide 2% fixed combination (TDFC) at 10:00 PM
Trial: 12867391
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% and dorzolamide 2% fixed combination (TDFC)
Trial: 10550446
Drug: hPTH (1-34)
RxNorm normalized name: (LEU27)-CYCLO(GLU22-LYS26)-HPTH-(1-31)-NH2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hPTH (1-34) 50 units weekly (L group)
Trial: 10550446
Drug: hPTH (1-34)
RxNorm normalized name: (LEU27)-CYCLO(GLU22-LYS26)-HPTH-(1-31)-NH2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hPTH (1-34) 100 units weekly (M group)
Trial: 10550446
Drug: hPTH (1-34)
RxNorm normalized name: (LEU27)-CYCLO(GLU22-LYS26)-HPTH-(1-31)-NH2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hPTH (1-34) 200 units weekly (H group)
Trial: 10550446
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (L, M, H)
Trial: 6375465
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg buprenorphine
Trial: 6375465
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg buprenorphine
Trial: 28558061
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose antimony
Trial: 28558061
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose antimony
Trial: 26775868
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of SNEDDS with conventional cinnarizine tablet
Trial: 21929736
Drug: Telmisartan (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40-80 mg daily)
Trial: 17468653
Drug: Xylitol (9.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol (9.6 g daily, 3 times a day)
Trial: 17468653
Drug: Control product
RxNorm normalized name: Patch test control product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control product (0.5 g daily, 3 times a day)
Trial: 9778325
Drug: 30000 IU
RxNorm normalized name: protease 30000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30000 IU heparin with 10.5 g SNAC
Trial: 9778325
Drug: 30000 IU
RxNorm normalized name: protease 30000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30000 IU heparin alone
Trial: 9778325
Drug: 10.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.5 g SNAC alone
Trial: 9778325
Drug: 2.25 g
RxNorm normalized name: Zosyn 2.25 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.25 g SNAC with heparin 30000 to 150000 IU
Trial: 8154249
Drug: Topical carteolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical carteolol 2%
Trial: 27893955
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) high dose
Trial: 27893955
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) medium dose
Trial: 18990531
Drug: Intravenous tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tigecycline
Trial: 9233110
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution IV
Trial: 7967102
Drug: Alcohol consumption
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol consumption (quantity in g/week and frequency in times/week)
Trial: 2502065
Drug: Fleroxacin 200
RxNorm normalized name: fleroxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 200 mg
Trial: 2502065
Drug: Fleroxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (200 or 400 mg)
Trial: 28328159
Drug: fosdagrocorat 10
RxNorm normalized name: Fosdagrocorat
DrugBank: Fosdagrocorat (DB12198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosdagrocorat 10 mg
Trial: 28328159
Drug: fosdagrocorat 25
RxNorm normalized name: Fosdagrocorat
DrugBank: Fosdagrocorat (DB12198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosdagrocorat 25 mg
Trial: 28328159
Drug: prednisone 5
RxNorm normalized name: prednisone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisone 5 mg
Trial: 19755817
Drug: S-1/Irinotecan (CPT-11)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1/Irinotecan (CPT-11) therapy
Trial: 16752738
Drug: Drugs and
RxNorm normalized name: Prostaglandin analogues, antiglaucoma drugs and miotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs and physiotherapeutic factors
Trial: 7954035
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg starting dose, increased to 8 mg if DBP > 95 mmHg)
Trial: 7954035
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg dose)
Trial: 2262897
Drug: Atropine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 2.0 mg
Trial: 2262897
Drug: Atropine 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 4.0 mg
Trial: 3579820
Drug: Atropine (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.5, 1.0, 2.0, 4.0 mg)
Trial: 3579820
Drug: Atropine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 2.0 mg and 4.0 mg
Trial: 30145102
Drug: 14-day bismuth-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day bismuth-containing quadruple therapy (group A)
Trial: 30145102
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy supplemented with Clostridium butyricum (group B)
Trial: 20093548
Drug: Apligraf (Organogenesis,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apligraf (Organogenesis, Inc) used in conjunction with standard therapy (sharp debridement, standard wound care, and off-loading)
Trial: 8532099
Drug: Psychoeducational training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational training for medication management, cognitive therapy, and work with relatives' groups
Trial: 8532099
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment including neuroleptic relapse prevention
Trial: 30939851
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol (60 mg kg‐1 24 h‐¹)
Trial: 29771088
Drug: Omeprazole enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole enteric‐coated capsules (20mg, Bid) for 1 month
Trial: 29771088
Drug: Omeprazole enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole enteric‐coated capsules (20mg, Bid) for 2 months
Trial: 29771088
Drug: Omeprazole enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole enteric‐coated capsules (20mg, Bid) for 3 months
Trial: 29771088
Drug: Omeprazole enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole enteric‐coated capsules (20mg, Bid) for 4 months
Trial: 26917577
Drug: Metformin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin therapy (2 g/day for 1 month)
Trial: 22138866
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate diet (HCHO; 7 g/kg body weight)
Trial: 22138866
Drug: Low carbohydrate
RxNorm normalized name: Low carbohydrate beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low carbohydrate diet (LCHO; 2 g/kg body weight)
Trial: 15743362
Drug: Octreotide 100
RxNorm normalized name: 1 ML octreotide 100 MCG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 100 microg intravenous bolus followed by a continuous infusion at 250 microg/h
Trial: 15743362
Drug: Terlipressin 2
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin 2 mg intravenous bolus
Trial: 9469362
Drug: Filgrastim 5
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim 5 microg/kg/day administered subcutaneously on days 3 through 9 after each BOP and on days 6 through 19 after each VIP, BEP, or EP cycle
Trial: 7630200
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone for patients < 40 years old
Trial: 2118326
Drug: Cefazolin (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1-g doses, three postoperative)
Trial: 2118326
Drug: Ceftriaxone (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1-g single dose preoperative)
Trial: 318965
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg of terbutaline sulfate
Trial: 318965
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of epinephrine hydrochloride
Trial: 23870605
Drug: Test formulation:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation: Amlodipine orotate 10 mg and valsartan 160 mg
Trial: 23870605
Drug: Reference formulation:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation: Amlodipine besylate 10 mg and valsartan 160 mg
Trial: 20980201
Drug: Telmisartan (Angiotensin-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (Angiotensin-receptor blocker)
Trial: 20980201
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (ramipril + telmisartan)
Trial: 17464690
Drug: Haloperidol or
RxNorm normalized name: haloperidol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol or risperidone for 8 weeks (exact dosage not specified)
Trial: 10211026
Drug: Thiopental 5
RxNorm normalized name: thiopental 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 5 mg kg‐1 (group TH)
Trial: 10211026
Drug: Alfentanil 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 10 micrograms kg‐1 and propofol 3 mg kg‐1 (group PAH)
Trial: 2180661
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy aimed at near normalization of blood glucose levels
Trial: 1776591
Drug: Chlormethiazole (384
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormethiazole (384 mg)
Trial: 30677465
Drug: Treat-and-extend (T&E)
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treat-and-extend (T&E) regimen with intravitreal ranibizumab at a dose of 0.5 mg
Trial: 30677465
Drug: Monthly dosing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly dosing regimen with intravitreal ranibizumab at a dose of 0.5 mg
Trial: 30677465
Drug: Monthly dosing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly dosing regimen
Trial: 28605779
Drug: DAPT (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT (aspirin and clopidogrel) for 24 months
Trial: 28605779
Drug: DAPT (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT (aspirin and clopidogrel) for 6 months
Trial: 19723755
Drug: Iodine-131 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-131 treatment
Trial: 19723755
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (antithyroid drugs)
Trial: 11561769
Drug: FEC (5-fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC (5-fluorouracil, epirubicin, and cyclophosphamide) - 9 cycles with dose escalation
Trial: 11561769
Drug: CTCb (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTCb (3 cycles of FEC followed by high-dose chemotherapy with alkylating agents)
Trial: 30630803
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (Dexmedetomidine + Continuous Positive Airway Pressure)
Trial: 26614548
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy only
Trial: 25885506
Drug: Intravenous 1
RxNorm normalized name: fat emulsion, intravenous 10% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 1 g tranexamic acid 20 min before skin incision
Trial: 2032107
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral lactulose (n = 35)
Trial: 2032107
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium deoxycholate (n = 32)
Trial: 2032107
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no specific treatment, n = 35)
Trial: 6754509
Drug: verapamil 120
RxNorm normalized name: verapamil 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 120 mg t.d.s.
Trial: 6754509
Drug: propranolol 160
RxNorm normalized name: propranolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol 160 mg b.d.
Trial: 26885881
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg DHEA (women)
Trial: 26885881
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg DHEA (men)
Trial: 26885881
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg T (men)
Trial: 21331473
Drug: HPMC capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC capsules
Trial: 8057000
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 or 100 mg/day)
Trial: 8057000
Drug: Dothiepin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dothiepin (75 or 150 mg/day)
Trial: 3127265
Drug: Ranitidine (H2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (H2 blocker)
Trial: 31051499
Drug: Pistachio-supplemented diet
RxNorm normalized name: Pistachio
DrugBank: Pistachio (DB10559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistachio-supplemented diet (PD, 50 E% carbohydrates and 33 E% fat, including 57 g pistachios/d)
Trial: 27488933
Drug: Ramosetron 0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.45 mg
Trial: 27488933
Drug: Ramosetron (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron (all doses)
Trial: 14562597
Drug: Prostaglandin F2
RxNorm normalized name: Prostaglandin F2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F2 alpha gel
Trial: 7599911
Drug: Metosil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metosil (10 mg)
Trial: 7599911
Drug: Plasil BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasil BP (10 mg)
Trial: 2221413
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g carnitine intravenously before cardiopulmonary bypass (CPB)
Trial: 2221413
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g carnitine intravenously before cardiopulmonary bypass (CPB)
Trial: 30798143
Drug: Parent administered
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent administered resilience component in conjunction with stuttering therapy
Trial: 30798143
Drug: Fluency therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluency therapy only
Trial: 25358227
Drug: Volar subcutaneous
RxNorm normalized name: Polar Freeze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volar subcutaneous digital block
Trial: 25358227
Drug: Dorsal two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsal two injections block
Trial: 18600509
Drug: urate-lowering agents
RxNorm normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: urate-lowering agents
Trial: 15980629
Drug: Telithromycin 800
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telithromycin 800 mg once daily for 5 or 7-10 days
Trial: 12054164
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy (mean dose, 0.18 IU/kg per week)
Trial: 7767551
Drug: Inhaled Atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Atrial Natriuretic Peptide (ANP)
Trial: 7767551
Drug: Thiorphan (NEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiorphan (NEP inhibitor) alone
Trial: 7767551
Drug: Inhaled Atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Atrial Natriuretic Peptide (ANP) with Thiorphan
Trial: 2181102
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral zidovudine therapy (80, 120, or 160 mg/m2/dose, with oral dose being 1.5 times the intravenous dosage)
Trial: 26359188
Drug: Intravitreal fluocinolone
RxNorm normalized name: Fluocinolone Acetonide Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal fluocinolone acetonide implant therapy
Trial: 11896510
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of calcium antagonists
Trial: 11896510
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment with calcium antagonists
Trial: 10573634
Drug: Microemulsion formulation
RxNorm normalized name: cyclosporine microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microemulsion formulation (Neoral)
Trial: 10573634
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation (Sandimmune)